Deleterious Effects of Obesity-Induced Low-Grade Inflammation
Abstract
There is a plethora of stimuli that can conduce to the development of inflammation. Generally speaking, inflammation can be defined as a localized response following tissue damage, and it can be subdivided into acute or chronic, depending on its duration. The noxious stimuli can be external, chemical, physical or biological in nature. The inflammatory response involves different immune cells and the production of a myriad of molecules. Drugs such as celecoxib and rofecoxib are regularly administered for chronic inflammation, attenuating the inflammatory response yet generating low to medium adverse effects due to drug nonspecificity or off-target effects. Obesity consists in weight increase associated with a caloric imbalance. The weight gain is associated to an increase in adipose tissue mass that is distributed in various body deposits. Development of obesity is multifactorial and carries with it the risk of generating grave consequences in the health and in the quality of life of patients. Due to the fact that obesity is linked to a state of chronic low inflammation, this further associates with the development of chronic conditions, amongst which we can find metabolic syndrome, cardiovascular disease, diabetes, respiratory problems, cancer, and recently it has highlighted as a risk factor in the development of severe COVID-19 symptomatology. In our country, it is estimated that more than half of the adult population is overweight, a statistic that has the tendency to continue increasing and which positions obesity as the epidemic of the upcoming decade.
Downloads
References
Villalba Herrera Ericka Wendie. Inflamación I. Rev Actual Clínica. 2014;43(1):2261-2265.
Chiappetta S, Sharma AM, Bottino V, Stier C. COVID-19 and the role of chronic inflammation in patientswith obesity. Int J Obes. 2020;44:1790-1792.
Zahedi H, Djalalinia S, Asayesh H, et al. A Higher Dietary Inflammatory Index Score is Associated with a Higher Risk of Incidence and Mortality of Cancer : A Comprehensive Systematic Review and Meta ‑ Analysis. Int J Prev Med. 2020;11:1-24. doi:10.4103/ijpvm.IJPVM
Thorburn AN, Macia L, Mackay CR. Diet, Metabolites, and “Western-Lifestyle” Inflammatory Diseases. Immunity. 2014;40(6):833-842. doi:10.1016/j.immuni.2014.05.014
Zinöcker MK, Lindseth IA. file:///F:/OBESIDAD/fisiopatologia-de-la-ciclooxigenasa-1-y-ciclooxigenasa-2.pdf. Nutrients. 2018;10:1-15. doi:10.3390/nu10030365
Barquera S, Rivera J. Country Focus Obesity in Mexico : rapid epidemiological transition and food industry interference in health policies. Lancet Diabetes Endocrinol. 2020;8(September):746-747. doi:10.1016/S2213-8587(20)30269-2
Rankin JA. Biological mediators of acute inflammation. AACN Clin Issues. 2004;15(1):3-17. doi:10.1097/00044067-200401000-00002
Vega Robledo GB. Inflamación. Rev Fac Med UNAM. 2008;51(5):220-222. http://www.medigraphic.com/pdfs/facmed/un-2008/un085k.pdf
González-Costa M, Padrón González AA. CIENCIAS BÁSICAS BIOMÉDICAS ARTÍCULO DE REVISIÓN La inflamación desde una perspectiva inmunológica: desafío a la Medicina en el siglo XXl Inflammation from an immunologic perspective: a challenge to medicine in the 21st century. Rev Habanera Ciencias Médicas. 2019;18(1):30-44. http://www.revhabanera.sld.cu/index.php/rhab/article/view/2445
Milagros Lisset León Regal, Ania Alvarado Borges, José Omar de Armas García, Luciano Miranda Alvarado Javier Antonio Varens Cedeño JÁC del S. Inflammatory Acute Response. Biochemical and Cellular Considerations. Rev Finlay. 2015;5(1):47-62.
Williams T, Morley J. Prostaglandinas como potenciadores del aumento de la permeabilidad vascular en la inflamación. Nature. 1973;246:215-217.
Van Bruggen N, Thibodeaux H, Palmer JT, et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest. 1999;104(11):1613-1620. doi:10.1172/JCI8218
León-Pedroza JI, González-Tapia LA, Del Olmo-Gil E, Castellanos-Rodríguez D, Escobedo G, González-Chávez A. Low-grade systemic inflammation and the development of metabolic diseases: From the molecular evidence to the clinical practice. Cir y Cir (English Ed. 2015;83(6):543-551. doi:10.1016/j.circir.2015.05.041
García Meijide JA, Gómez-Reino Carnota JJ. Fisiopatología de la ciclooxigenasa-1 y ciclooxigenasa-2. Rev Esp Reumatol. 2000;27(1):33-35.
Lezana M, Borja V, Blanco M, et al. OBESIDAD EN MÉXICO (Primera de tres partes). Sist Nac Vigil Epidemiológica. 2010;27(43):1-27.
Guerra Cabrera C, Vila Díaz J, Apolinaire Pennini J, Cabrera Romero A, Santana Carballosa I, Almaguer Sabina P. Risk factors associate with overweight and obesity in adolescents. MediSur. 2009;7(2):25-34.
Palou A, Luisa Bonet M. Challenges in obesity research. Nutr Hosp. 2013;28(5):144-153. doi:10.3305/nh.2013.28.sup5.6930
Leveau-Bartra H, Leveau-Bartra OA, Ausejo-Galarza JR, et al. Obesidad Como Factor De Riesgo Para Mortalidad Por Covid-19. Rev Médica Panacea. 2020;9(3):184-188. doi:10.35563/rmp.v9i3.372
Claudia P. Sánchez-Castillo, Edgar Pichardo-Ontiveros PL-R. Epidemiología de la obesidad. Medigraphic. 2004;140(2):3-20.
Mohsen-Kanson T, Wdziekonski B, Villageois P, et al. Development of Adipose Cells. In: Bastard J-P, Feve B, eds. Physiology and Physiopathology of Adipose Tissue. Vol 9782817803. Springer; 2013:3-15. doi:10.1007/978-2-8178-0343-2_11
Leroux MB. Tejido adiposo. Arch argent dermatol. Published online 2009:183-192.
Cannon B, Hedin A, Nedergaard J. Exclusive occurrence of thermogenin antigen in brown adipose tissue. FEBS Lett. 1982;150(1):129-132. doi:10.1016/0014-5793(82)81319-7
Sánchez JC, Romero CR, Muñoz LV, Alonso Rivera R. El órgano adiposo, un arcoiris de regulación metabólica y endocrina. Rev Cuba Endocrinol. 2016;27(1):105-119.
Vanderwall C, Clark RR, Eickhoff J, Carrel AL. BMI is a poor predictor of adiposity in young overweight and obese children. BMC Pediatr. 2017;17(1):135-140. doi:10.1186/s12887-017-0891-z
Martínez LM. Revista Cubana de Obstetricia y. Rev Cuba Obstet y Ginecol. 2018;2(October):1-16. doi:10.1590/SciELOPreprints.1200
Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity1. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, others. MCP-1 contributes to m. J Clin Invest. 2006;116(6):1494-1505. doi:10.1172/JCI26498DS1
Shimobayashi M, Albert V, Woelnerhanssen B, et al. Insulin resistance causes inflammation in adipose tissue. J Clin Invest. 2018;128(4):1538-1550. doi:10.1172/JCI96139
Rodríguez López CP, Torres MCG, Aguilar Salinas CA, Medina ON. Mecanismos inmunológicos involucrados en la obesidad. Investig Clin. 2017;58(2):175-196.
Liu K, Zhao E, Ilyas G, et al. Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization. Autophagy. 2015;11(2):271-284. doi:10.1080/15548627.2015.1009787
Jeong H, Lee C, Cheng C, Chou HC, Yang HJ, Bae H. Targeting of adipose tissue macrophages by bee venom phospholipase A2 attenuates high-fat diet-induced obesity. Int J Obes. 2021;45(8):1656-1667. doi:10.1038/s41366-021-00823-4
Abarca A. Ejercicio como tratamiento anti-inflamatorio. Med Leg Costa Rica. 2016;33(1):228-233.
Chávez R, Zamarreño J. Ejercicio físico y actividad física en el abordaje terapéutico de la obesidad y el sedentarismo. Rev Cuba Med Física y Rehabil. 2016;8(2):215-230. http://www.sld.cu/sitios/revrehabilitacion/http://www.sld.cu/sitios/revrehabilitacion/
Lizarzaburu Robles JC. Síndrome metabólico: concepto y aplicación práctica. An la Fac Med. 2014;74(4):315. doi:10.15381/anales.v74i4.2705
Enrique P, Soca; I M, Niño A, Ii P. Consecuencias de La Obesidad Consequences of Obesity. Vol 20.; 2009. http://scielo.sld.cu84
Fernández-Travieso JC. Sindrome Metabolico y Riesgo Cardiovascular. Rev CENIC Ciencias Biológicas. 2016;47(2):106-119.
López-Jiménez F, Cortés-Bergoderi M. Obesidad y corazón. Rev Esp Cardiol. 2011;64(2):140-149. doi:10.1016/j.recesp.2010.10.010
Sánchez R C, Ibáñez C, Klaassen J. Obesidad y cáncer: la tormenta perfecta. Rev Med Chil. 2014;142(2):211-221. doi:10.4067/s0034-98872014000200010
Cervera R, Espinosa G, Ramos M, et al. Respuesta Inmunoinflamatoria en la COVID-19. Published online 2020:24.
Pérez Castrillón J, Casado E, Corral Gudino L, Gómez Alonso C, Peris P, Riancho J. COVID-19 y vitamina D. Documento de posición de la Sociedad Española de Investigación Ósea y del Metabolismo Mineral (SEIOMM). Rev Osteoporos y Metab Miner. 2020;12(4):155-159. doi:10.4321/s1889-836x2020000400009
Rosario V, Miranda M. Relación entre el SARS-CoV-2, la microbiota intestinal y la presencia de síntomas digestivos Relationship between SARS-CoV-2, gut microbiota and the presence of digestive symptoms. 2021;93(2):1-9. http://orcid.org/0000-0002-5366-8018
Déctor Lira DM. Microbiota. Med Interna Mex. 2020;36(Supl 4):34-36.
Petrova D, Salamanca-Fernández E, Rodríguez Barranco M, Navarro Pérez P, Jiménez Moleón JJ, Sánchez MJ. Obesity as a risk factor in COVID-19: Possible mechanisms and implications. Aten Primaria. 2020;52(7):496-500. doi:10.1016/j.aprim.2020.05.003
